MA49773A - Combinaisons d'antagonistes de pd-1 et d'agonistes de sting benzo[b - Google Patents

Combinaisons d'antagonistes de pd-1 et d'agonistes de sting benzo[b

Info

Publication number
MA49773A
MA49773A MA049773A MA49773A MA49773A MA 49773 A MA49773 A MA 49773A MA 049773 A MA049773 A MA 049773A MA 49773 A MA49773 A MA 49773A MA 49773 A MA49773 A MA 49773A
Authority
MA
Morocco
Prior art keywords
sting
agonists
benzo
antagonists
combinations
Prior art date
Application number
MA049773A
Other languages
English (en)
French (fr)
Inventor
Saso Cemerski
Jared N Cumming
Johnny E Kopinja
Samanthi A Perera
Benjamin Wesley Trotter
Archie Ngai-Chiu Tse
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA49773A publication Critical patent/MA49773A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA049773A 2017-08-04 2018-07-30 Combinaisons d'antagonistes de pd-1 et d'agonistes de sting benzo[b MA49773A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762541180P 2017-08-04 2017-08-04

Publications (1)

Publication Number Publication Date
MA49773A true MA49773A (fr) 2021-04-21

Family

ID=65234179

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049773A MA49773A (fr) 2017-08-04 2018-07-30 Combinaisons d'antagonistes de pd-1 et d'agonistes de sting benzo[b

Country Status (8)

Country Link
US (1) US11312772B2 (https=)
EP (1) EP3661499A4 (https=)
JP (1) JP2020529421A (https=)
AU (1) AU2018311965A1 (https=)
CA (1) CA3071537A1 (https=)
MA (1) MA49773A (https=)
RU (1) RU2020109328A (https=)
WO (1) WO2019027857A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3523287T (pt) * 2016-10-04 2021-10-06 Merck Sharp & Dohme Compostos de benzo[b]tiofeno como agonistas de sting
WO2019046511A1 (en) 2017-08-31 2019-03-07 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE
JP7570235B2 (ja) 2018-05-25 2024-10-21 インサイト・コーポレイション Ｓｔｉｎｇ活性化剤としての三環式複素環式化合物
WO2020028566A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Heteroaryl amide compounds as sting activators
US11008344B2 (en) 2018-07-31 2021-05-18 Incyte Corporation Tricyclic heteroaryl compounds as STING activators
TWI855000B (zh) 2018-10-11 2024-09-11 日商小野藥品工業股份有限公司 Ｓｔｉｎｇ促效化合物
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
WO2020146237A1 (en) 2019-01-07 2020-07-16 Incyte Corporation Heteroaryl amide compounds as sting activators
BR112021018947A2 (pt) * 2019-03-28 2022-02-08 Lupin Ltd Compostos macrocíclicos como agonistas de sting
EP3964504A4 (en) * 2019-04-30 2022-12-28 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. AMINOPYRIMIDINE COMPOUND, METHOD OF PRODUCTION THEREOF AND USE THEREOF
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
TW202116330A (zh) * 2019-07-09 2021-05-01 日商武田藥品工業股份有限公司 Sting 促效劑及檢查點抑制劑之投與
CR20220029A (es) 2019-07-22 2022-03-14 Lupin Ltd Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
JP7843695B2 (ja) 2019-08-02 2026-04-10 メルサナ セラピューティクス インコーポレイテッド がんの処置用のＳＴＩＮＧ（インターフェロン遺伝子刺激因子）アゴニストとしてのビス－［Ｎ－（（５－カルバモイル）－１Ｈ－ベンゾ［ｄ］イミダゾール－２－イル）－ピラゾール－５－カルボキサミド］誘導体および関連化合物
IL296901A (en) 2020-04-02 2022-12-01 Mersana Therapeutics Inc Antibody-drug conjugates comprising sting agonists
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
CN116490244A (zh) * 2020-11-18 2023-07-25 武田药品工业株式会社 Sting激动剂、检查点抑制剂和辐射的施用
JP2023550740A (ja) * 2020-11-18 2023-12-05 武田薬品工業株式会社 Ｓｔｉｎｇアゴニスト、チェックポイント阻害剤、及び放射線の投与
CN113429384B (zh) * 2021-05-12 2022-04-08 中山大学附属第五医院 一类干扰素基因刺激因子靶向的放射性pet显像剂
CN113521303B (zh) * 2021-07-07 2024-01-02 中山大学附属第一医院 一种共同负载pd-l1抗体和sting激动剂的纳米囊泡及其制备方法与应用
CN115772154B (zh) * 2021-09-08 2024-04-30 上海交通大学 一类含有氘取代的苯并噻吩类衍生物及其制备与用途
EP4490195A4 (en) * 2022-03-07 2026-02-11 Arima Genomics Inc METHODS FOR SELECTING AND TREATMENT OF CANCER PATIENTS CANDIDATES FOR TREATMENT WITH PD-1 PATHWAY INHIBITORS
WO2026078593A1 (en) 2024-10-08 2026-04-16 Sun Pharma Advanced Research Company Limited Sting agonists and antibody drug conjugates thereof

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB532822A (en) 1939-08-11 1941-01-31 John David Kendall Improvements in and relating to the production of ª‡-coumarilyl and ª‡-thionaphthenoyl-acetic acid esters
US4342691A (en) 1980-04-28 1982-08-03 American Cyanamid Company ω-Heteroaroyl(propionyl or butyryl)-L-prolines
US4342689A (en) 1980-04-28 1982-08-03 American Cyanamid Company ω-Heteroaroyl(propionyl or butyryl)-L-prolines
US4342690A (en) 1980-04-28 1982-08-03 American Cyanamid Company ω-Heteroaroyl(propionyl or butyryl)-L-prolines
US4299769A (en) 1980-04-28 1981-11-10 American Cyanamid Company ω-Heteroaroyl(propionyl or butyryl)-L-prolines
EP0146243A1 (en) 1983-10-31 1985-06-26 Merck Frosst Canada Inc. Lipoxygenase inhibitors
EP0350990B1 (en) 1988-07-11 1995-09-20 Akzo Nobel N.V. Pyridazinone derivatives
ATE188379T1 (de) 1992-10-14 2000-01-15 Merck & Co Inc Fibrinogenrezeptor-antagonisten
US5569655A (en) 1993-09-14 1996-10-29 Sterling Winthrop Inc. Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof
JP2002517390A (ja) 1998-06-03 2002-06-18 メルク エンド カムパニー インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬
US6262055B1 (en) 1998-06-03 2001-07-17 Merck & Co., Inc. HIV integrase inhibitors
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
WO2001070675A2 (en) 2000-03-24 2001-09-27 Methylgene, Inc. Inhibitors of histone deacetylase
US6448288B1 (en) 2000-05-17 2002-09-10 University Of Massachusetts Cannabinoid drugs
JP2004531238A (ja) 2001-02-26 2004-10-14 ファーマ パシフィック プロプライエタリー リミテッド インターフェロン−アルファ誘導遺伝子
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
CN1845914A (zh) 2003-09-02 2006-10-11 默克公司 用于治疗眼压过高的眼用组合物
WO2005089777A1 (en) 2004-03-15 2005-09-29 Karaolis David K R A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
AU2006304897B2 (en) 2005-10-18 2012-07-12 Janssen Pharmaceutica N.V. Method of inhibiting FLT3 kinase
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
KR101523391B1 (ko) 2006-12-27 2015-05-27 에모리 유니버시티 감염 및 종양 치료를 위한 조성물 및 방법
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
US8664255B2 (en) 2008-10-20 2014-03-04 The Texas A&M University System Inhibitors of mycobacterium tuberculosis malate synthase, methods of making and uses thereof
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2012068702A1 (zh) 2010-11-23 2012-05-31 中国医学科学院医药生物技术研究所 苯并五元不饱和杂环类化合物及其制备方法
JP5887947B2 (ja) 2011-03-28 2016-03-16 ソニー株式会社 透明導電膜、ヒータ、タッチパネル、太陽電池、有機ｅｌ装置、液晶装置および電子ペーパ
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
MX368257B (es) 2011-08-01 2019-09-26 Genentech Inc Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
EP2858722B8 (en) 2012-06-08 2018-02-21 Aduro BioTech, Inc. Compostions and methods for cancer immunotherapy
US9695212B2 (en) 2012-12-13 2017-07-04 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
EP2934598B1 (en) 2012-12-19 2018-04-18 Board Of Regents, The University Of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
US9840533B2 (en) 2013-04-29 2017-12-12 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
WO2014189806A1 (en) 2013-05-18 2014-11-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 癌処置としてのｓｔｉｎｇアゴニストの使用
WO2015074145A1 (en) 2013-11-22 2015-05-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
US9315523B2 (en) 2013-12-06 2016-04-19 Rutgers, The State University Of New Jersey Cyclic dinucleosides
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
CN103908468B (zh) 2014-04-21 2017-02-08 上海捌加壹医药科技有限公司 环二核苷酸cGAMP在制备抗肿瘤药物中的应用
CR20160564A (es) 2014-06-04 2017-01-20 Glaxosmithkline Ip Dev Ltd Dinucleótidos cíclicos como moduladores de sting
US20170121315A1 (en) 2014-06-12 2017-05-04 Bayer Pharma Aktiengesellschaft Heterobicyclically substituted 4-oxobutane acid derivatives and use thereof
US10695426B2 (en) * 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
WO2016096577A1 (en) 2014-12-16 2016-06-23 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
EP3546473B1 (en) 2014-12-16 2025-12-10 Kayla Therapeutics Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction
US20180344758A1 (en) 2014-12-17 2018-12-06 Lipogen Llc Method of Treating Cancer with cGAMP or cGAsMP
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
EA035817B1 (ru) 2015-03-10 2020-08-14 Адуро Байотек, Инк. Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
TW201717968A (zh) 2015-07-14 2017-06-01 春季銀行製藥公司 誘導ｒｉｇ－ｉ和其他模式辨識受體之化合物及組成物
CA3030582A1 (en) 2015-07-22 2017-01-26 The Royal Institution For The Advancement Of Learning/Mcgill University Compounds and uses thereof in the treatment of cancers and other medical conditions
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
KR102222186B1 (ko) 2015-08-13 2021-03-03 머크 샤프 앤드 돔 코포레이션 Sting 효능제로서 시클릭 디-뉴클레오티드 화합물
US9809597B2 (en) 2015-08-20 2017-11-07 The Board Of Trustees Of The Leland Stanford Junior University Ganciclovir derivatives for modulating innate and adaptive immunity and for use in immunotherapy
JP2018534295A (ja) 2015-10-28 2018-11-22 アドゥロ バイオテック，インク． 「インターフェロン遺伝子刺激因子」依存性シグナル伝達を活性化するための組成物および方法
US20170146519A1 (en) 2015-11-20 2017-05-25 Oregon Health & Science University Sting agonists and methods of selecting sting agonists
CN107849084B (zh) 2015-12-03 2021-09-14 葛兰素史密斯克莱知识产权发展有限公司 作为sting调节剂的环状嘌呤二核苷酸
DE212016000029U1 (de) 2015-12-07 2017-07-30 Opi Vi - Ip Holdco Llc Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
ES2986067T3 (es) * 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
KR102789862B1 (ko) 2016-01-11 2025-04-03 인네이트 튜머 이뮤니티, 인코포레이티드 Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드
US10723756B2 (en) 2016-01-11 2020-07-28 Innate Tumor Immunity Inc. Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
NZ746112A (en) 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節物質として有用な複素環アミド
PT3440076T (pt) 2016-04-07 2022-07-29 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas úteis como modeladores de proteína
WO2017216726A1 (en) 2016-06-13 2017-12-21 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as inhibitors of dnmt1
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
PT3523287T (pt) * 2016-10-04 2021-10-06 Merck Sharp & Dohme Compostos de benzo[b]tiofeno como agonistas de sting

Also Published As

Publication number Publication date
EP3661499A1 (en) 2020-06-10
WO2019027857A1 (en) 2019-02-07
RU2020109328A3 (https=) 2021-11-09
CA3071537A1 (en) 2019-02-07
RU2020109328A (ru) 2021-09-06
US20210130466A1 (en) 2021-05-06
US11312772B2 (en) 2022-04-26
EP3661499A4 (en) 2021-04-21
AU2018311965A1 (en) 2020-02-13
JP2020529421A (ja) 2020-10-08

Similar Documents

Publication Publication Date Title
MA49773A (fr) Combinaisons d'antagonistes de pd-1 et d'agonistes de sting benzo[b
EP3454844A4 (en) COMBINATION THERAPIES OF HDAC INHIBITORS AND PD-1 INHIBITORS
IL271460A (en) Assessing transplant complication risk with total cell-free dna
EP3558358A4 (en) COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDIC STING AGONISTS FOR CANCER TREATMENT
EP3481814A4 (en) TETRAHYDRONAPHTHYRIDINPENTANAMID integrin antagonists
MA44990A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1
IL292692A (en) Mrgprx2 antagonists and uses thereof
IL272016B (en) Pyrrolidine derivatives and their use as tlr7/8 antagonists
EP3684361A4 (en) SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING
PT3621960T (pt) Tienopiridinas e benzotiofenos úteis como inibidores de irak4
MA51066A (fr) Inhibiteurs d'intégrine
EP3756379C0 (en) Sftd and anr specific reporting
MA52117A (fr) Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
EP3515296A4 (en) TISSUE VIABILITY MEASUREMENT
EP3596053A4 (en) FARNESOID X RECEPTOR AGONISTS AND THEIR USES
EP3860977A4 (en) INTEGRIN ANTAGONISTS
EP3568159A4 (en) PSGL-1 ANTAGONISTS AND THEIR USES
EP3672650A4 (en) Hydrogel for tissue engineering and bioprinting
EP3444254A4 (en) HETEROCYCLICALLY SUBSTITUTED PYRIDINOPYRIMIDINONE DERIVATIVE AS CDK INHIBITOR AND USE THEREOF
EP3632898A4 (en) EP4 ANTAGONIST
EP3543240A4 (en) URAT1 INHIBITOR AND USE THEREOF
PL3662234T3 (pl) Urządzenie i sposób ulepszonego monitorowania oprysku
MA46540A (fr) Agonistes du récepteur de l'apéline (apj) hétérocyclique et leurs utilisations
IL292693A (en) Mrgprx2 antagonists and uses thereof
EP3643776A4 (en) CORNEAL ENDOTAL CELL MARKER AND ITS USES